GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » 5-Year Yield-on-Cost %

Syncom Formulation (India) (NSE:SYNCOMF) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) 5-Year Yield-on-Cost %?

Syncom Formulation (India)'s yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Syncom Formulation (India)'s 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Syncom Formulation (India)'s highest Yield on Cost was 2.22. The lowest was 0.00. And the median was 0.66.


NSE:SYNCOMF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Syncom Formulation (India)'s 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s 5-Year Yield-on-Cost % falls into.



Syncom Formulation (India) 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Syncom Formulation (India) is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Syncom Formulation (India)  (NSE:SYNCOMF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Syncom Formulation (India) 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) Headlines

No Headlines